MIW815 (ADU-S100) is the first synthetic cyclic dinucleotide (CDN) STING agonist to enter clinical trials, marking the beginning of therapeutic exploration targeting the STING pathway in cancer immunotherapy. The gene discussed is STING1; the disease is cancer.